ArticleThe Lancet. Global health2017
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study.
Article in The Lancet. Global health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Association Between Cytomegalovirus Infection and Tuberculosis Disease: A Systematic Review and Meta-Analysis of Epidemiological Studies.The Journal of infectious diseases · 2023Pooled it
- Duration and determinants of delayed tuberculosis diagnosis and treatment in high-burden countries: a mixed-methods systematic review and meta-analysis.Respiratory research · 2021Pooled it
- The potential impact of reduced international donor funding on the household economic burden of tuberculosis in low- and middle-income countries: A modeling study.PLoS medicine · 2026Article
- The influence of provider payment mechanisms on TB service provider behavior in Indonesia: insights from National Health Insurance data and provider perspectives.Frontiers in public health · 2025Article
- Estimating the health and macroeconomic burdens of tuberculosis in India, 2021-2040: A fully integrated modelling study.PLoS medicine · 2024Article
- Estimation of potential social support requirement for tuberculosis patients in India.Health policy and planning · 2024Article
- Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.The Lancet. Global health · 2024Article
- Is convenience really king? Comparative evaluation of catastrophic costs due to tuberculosis in the public and private healthcare sectors of Viet Nam: a longitudinal patient cost study.Infectious diseases of poverty · 2024Article
- Determinants of catastrophic costs among households affected by multi-drug resistant tuberculosis in Ho Chi Minh City, Viet Nam: a prospective cohort study.BMC public health · 2023Article
- The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries.BMJ global health · 2023Article
- Article
- Considering equity in priority setting using transmission models: Recommendations and data needs.Epidemics · 2022Review
- Living with tuberculosis: a qualitative study of patients' experiences with disease and treatment.BMC public health · 2022Article
- Predicting the impact of control strategies on the tuberculosis burden in South and North Korea using a mathematical model.BMJ global health · 2021Article
- How to reduce household costs for people with tuberculosis: a longitudinal costing survey in Nepal.Health policy and planning · 2021Article
- Incorporating equity in infectious disease modeling: Case study of a distributional impact framework for measles transmission.Vaccine · 2021Article
- Health care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, Zimbabwe: A prospective cohort study.PloS one · 2021Article
- Rising Catastrophic Expenditure on Households Due to Tuberculosis: Is India Moving Away From the END-TB Goal?Frontiers in public health · 2021Article
- How much do Indians pay for tuberculosis treatment? A cost analysis.Public health action · 2020Article
- Nomogram for individualized prediction of incident multidrug-resistant tuberculosis after completing pulmonary tuberculosis treatment.Scientific reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 8 institutions in 7 countries.
Funding
Abstract
backgroundThe economic burden on households affected by tuberculosis through costs to patients can be catastrophic. WHO's End TB Strategy recognises and aims to eliminate these potentially devastating economic effects. We assessed whether aggressive expansion of tuberculosis services might reduce catastrophic costs.
methodsWe estimated the reduction in tuberculosis-related catastrophic costs with an aggressive expansion of tuberculosis services in India and South Africa from 2016 to 2035, in line with the End TB Strategy. Using modelled incidence and mortality for tuberculosis and patient-incurred cost estimates, we investigated three intervention scenarios: improved treatment of drug-sensitive tuberculosis; improved treatment of multidrug-resistant tuberculosis; and expansion of access to tuberculosis care through intensified case finding (South Africa only). We defined tuberculosis-related catastrophic costs as the sum of direct medical, direct non-medical, and indirect costs to patients exceeding 20% of total annual household income. Intervention effects were quantified as changes in the number of households incurring catastrophic costs and were assessed by quintiles of household income.
findingsIn India and South Africa, improvements in treatment for drug-sensitive and multidrug-resistant tuberculosis could reduce the number of households incurring tuberculosis-related catastrophic costs by 6-19%. The benefits would be greatest for the poorest households. In South Africa, expanded access to care could decrease household tuberculosis-related catastrophic costs by 5-20%, but gains would be seen largely after 5-10 years.
interpretationAggressive expansion of tuberculosis services in India and South Africa could lessen, although not eliminate, the catastrophic financial burden on affected households.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.